Targeting cGAS pharmacologically (using inhibitor RU.521) or genetically (siRNA transfection) can effectively reduce the escalation of IPF-LFs and IPF-ACEs senescence and the production of IL-6, an archetypal SASP cytokine. The gene discussed is IL6; the disease is idiopathic pulmonary fibrosis.